O ROURKE & COMPANY Inc Has $864,000 Stake in GSK plc (NYSE:GSK)

O ROURKE & COMPANY Inc lowered its stake in shares of GSK plc (NYSE:GSK) by 12.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,146 shares of the pharmaceutical company’s stock after selling 2,894 shares during the quarter. O ROURKE & COMPANY Inc’s holdings in GSK were worth $864,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in GSK. Personal CFO Solutions LLC lifted its holdings in shares of GSK by 2.7% during the 4th quarter. Personal CFO Solutions LLC now owns 10,087 shares of the pharmaceutical company’s stock worth $374,000 after acquiring an additional 263 shares during the period. Chapin Davis Inc. boosted its holdings in shares of GSK by 2.2% in the 1st quarter. Chapin Davis Inc. now owns 14,231 shares of the pharmaceutical company’s stock valued at $610,000 after purchasing an additional 300 shares in the last quarter. Dorsey & Whitney Trust CO LLC increased its stake in shares of GSK by 2.9% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 10,986 shares of the pharmaceutical company’s stock valued at $407,000 after purchasing an additional 306 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in shares of GSK by 23.1% during the 4th quarter. Jones Financial Companies Lllp now owns 1,633 shares of the pharmaceutical company’s stock worth $61,000 after buying an additional 306 shares in the last quarter. Finally, Cape Investment Advisory Inc. lifted its position in shares of GSK by 4.8% during the 4th quarter. Cape Investment Advisory Inc. now owns 6,686 shares of the pharmaceutical company’s stock worth $248,000 after buying an additional 308 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Trading Down 0.3 %

NYSE GSK traded down $0.12 during trading hours on Monday, reaching $38.38. The company’s stock had a trading volume of 2,872,525 shares, compared to its average volume of 3,655,897. The firm has a fifty day simple moving average of $42.51 and a 200-day simple moving average of $41.23. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58. GSK plc has a 52 week low of $33.67 and a 52 week high of $45.92. The stock has a market cap of $79.54 billion, a P/E ratio of 13.90, a P/E/G ratio of 1.16 and a beta of 0.64.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.15. GSK had a net margin of 14.62% and a return on equity of 51.54%. The firm had revenue of $9.34 billion during the quarter, compared to the consensus estimate of $8.98 billion. Equities analysts forecast that GSK plc will post 4.11 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be given a $0.3762 dividend. This represents a $1.50 dividend on an annualized basis and a dividend yield of 3.92%. The ex-dividend date is Thursday, May 16th. This is a positive change from GSK’s previous quarterly dividend of $0.36. GSK’s payout ratio is 53.26%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Citigroup upgraded GSK to a “strong-buy” rating in a research report on Monday, June 24th. The Goldman Sachs Group initiated coverage on shares of GSK in a research report on Thursday, May 30th. They set a “neutral” rating and a $47.00 price objective for the company. Berenberg Bank raised shares of GSK to a “strong-buy” rating in a research note on Thursday, June 20th. Finally, Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $47.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.